Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients

John D. Andersen, Kristin L.M. Boylan, Ronald Jemmerson, Melissa A. Geller, Benjamin Misemer, Katherine M. Harrington, Starchild Weivoda, Bruce A. Witthuhn, Peter Argenta, Rachel Isaksson Vogel, Amy P.N. Skubitz

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background. New biomarkers that replace or are used in conjunction with the current ovarian cancer diagnostic antigen, CA125, are needed for detection of ovarian cancer in the presurgical setting, as well as for detection of disease recurrence. We previously demonstrated the upregulation of leucine-rich alpha-2-glycoprotein-1 (LRG1) in the sera of ovarian cancer patients compared to healthy women using quantitative mass spectrometry. Methods. LRG1 was quantified by ELISA in serum from two relatively large cohorts of women with ovarian cancer and benign gynecological disease. The expression of LRG1 in ovarian cancer tissues and cell lines was examined by gene microarray, reverse-transcriptase polymerase chain reaction (RT-PCR), Western blot, immunocytochemistry and mass spectrometry. Results. Mean serum LRG1 was higher in 58 ovarian cancer patients than in 56 healthy women (89.33 77.90 vs. 42.99 9.88 ug/ml; p = 0.0008) and was highest among stage III/IV patients. In a separate set of 193 pre-surgical samples, LRG1 was higher in patients with serous or clear cell ovarian cancer (145.82 65.99 ug/ml) compared to patients with benign gynecological diseases (82.53 76.67 ug/ml, p < 0.0001). CA125 and LRG1 levels were moderately correlated (r = 0.47, p < 0.0001). LRG1 mRNA levels were higher in ovarian cancer tissues and cell lines compared to their normal counterparts when analyzed by gene microarray and RT-PCR. LRG1 protein was detected in ovarian cancer tissue samples and cell lines by immunocytochemistry and Western blotting. Multiple iosforms of LRG1 were observed by Western blot and were shown to represent different glycosylation states by digestion with glycosidase. LRG1 protein was also detected in the conditioned media of ovarian cancer cell culture by ELISA, Western blotting, and mass spectrometry. Conclusions. Serum LRG1 was significantly elevated in women with ovarian cancer compared to healthy women and women with benign gynecological disease, and was only moderately correlated with CA125. Ovarian cancer cells secrete LRG1 and may contribute directly to the elevated levels of LRG1 observed in the serum of ovarian cancer patients. Future studies will determine whether LRG1 may serve as a biomarker for presurgical diagnosis, disease recurrence, and/or as a target for therapy.

Original languageEnglish (US)
Article number21
JournalJournal of Ovarian Research
Volume3
Issue number1
DOIs
StatePublished - Oct 14 2010

Fingerprint

Leucine
Ovarian Neoplasms
Glycoproteins
Serum
Neoplasms
Western Blotting
Mass Spectrometry
Reverse Transcriptase Polymerase Chain Reaction
Cell Line
CA-125 Antigen
Biomarkers
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Recurrence
Glycoside Hydrolases
Conditioned Culture Medium
Glycosylation
Genes
Digestion
Proteins

Cite this

Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients. / Andersen, John D.; Boylan, Kristin L.M.; Jemmerson, Ronald; Geller, Melissa A.; Misemer, Benjamin; Harrington, Katherine M.; Weivoda, Starchild; Witthuhn, Bruce A.; Argenta, Peter; Vogel, Rachel Isaksson; Skubitz, Amy P.N.

In: Journal of Ovarian Research, Vol. 3, No. 1, 21, 14.10.2010.

Research output: Contribution to journalArticle

@article{c40e4c95580b44c68b31536988ceffc0,
title = "Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients",
abstract = "Background. New biomarkers that replace or are used in conjunction with the current ovarian cancer diagnostic antigen, CA125, are needed for detection of ovarian cancer in the presurgical setting, as well as for detection of disease recurrence. We previously demonstrated the upregulation of leucine-rich alpha-2-glycoprotein-1 (LRG1) in the sera of ovarian cancer patients compared to healthy women using quantitative mass spectrometry. Methods. LRG1 was quantified by ELISA in serum from two relatively large cohorts of women with ovarian cancer and benign gynecological disease. The expression of LRG1 in ovarian cancer tissues and cell lines was examined by gene microarray, reverse-transcriptase polymerase chain reaction (RT-PCR), Western blot, immunocytochemistry and mass spectrometry. Results. Mean serum LRG1 was higher in 58 ovarian cancer patients than in 56 healthy women (89.33 77.90 vs. 42.99 9.88 ug/ml; p = 0.0008) and was highest among stage III/IV patients. In a separate set of 193 pre-surgical samples, LRG1 was higher in patients with serous or clear cell ovarian cancer (145.82 65.99 ug/ml) compared to patients with benign gynecological diseases (82.53 76.67 ug/ml, p < 0.0001). CA125 and LRG1 levels were moderately correlated (r = 0.47, p < 0.0001). LRG1 mRNA levels were higher in ovarian cancer tissues and cell lines compared to their normal counterparts when analyzed by gene microarray and RT-PCR. LRG1 protein was detected in ovarian cancer tissue samples and cell lines by immunocytochemistry and Western blotting. Multiple iosforms of LRG1 were observed by Western blot and were shown to represent different glycosylation states by digestion with glycosidase. LRG1 protein was also detected in the conditioned media of ovarian cancer cell culture by ELISA, Western blotting, and mass spectrometry. Conclusions. Serum LRG1 was significantly elevated in women with ovarian cancer compared to healthy women and women with benign gynecological disease, and was only moderately correlated with CA125. Ovarian cancer cells secrete LRG1 and may contribute directly to the elevated levels of LRG1 observed in the serum of ovarian cancer patients. Future studies will determine whether LRG1 may serve as a biomarker for presurgical diagnosis, disease recurrence, and/or as a target for therapy.",
author = "Andersen, {John D.} and Boylan, {Kristin L.M.} and Ronald Jemmerson and Geller, {Melissa A.} and Benjamin Misemer and Harrington, {Katherine M.} and Starchild Weivoda and Witthuhn, {Bruce A.} and Peter Argenta and Vogel, {Rachel Isaksson} and Skubitz, {Amy P.N.}",
year = "2010",
month = "10",
day = "14",
doi = "10.1186/1757-2215-3-21",
language = "English (US)",
volume = "3",
journal = "Journal of Ovarian Research",
issn = "1757-2215",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients

AU - Andersen, John D.

AU - Boylan, Kristin L.M.

AU - Jemmerson, Ronald

AU - Geller, Melissa A.

AU - Misemer, Benjamin

AU - Harrington, Katherine M.

AU - Weivoda, Starchild

AU - Witthuhn, Bruce A.

AU - Argenta, Peter

AU - Vogel, Rachel Isaksson

AU - Skubitz, Amy P.N.

PY - 2010/10/14

Y1 - 2010/10/14

N2 - Background. New biomarkers that replace or are used in conjunction with the current ovarian cancer diagnostic antigen, CA125, are needed for detection of ovarian cancer in the presurgical setting, as well as for detection of disease recurrence. We previously demonstrated the upregulation of leucine-rich alpha-2-glycoprotein-1 (LRG1) in the sera of ovarian cancer patients compared to healthy women using quantitative mass spectrometry. Methods. LRG1 was quantified by ELISA in serum from two relatively large cohorts of women with ovarian cancer and benign gynecological disease. The expression of LRG1 in ovarian cancer tissues and cell lines was examined by gene microarray, reverse-transcriptase polymerase chain reaction (RT-PCR), Western blot, immunocytochemistry and mass spectrometry. Results. Mean serum LRG1 was higher in 58 ovarian cancer patients than in 56 healthy women (89.33 77.90 vs. 42.99 9.88 ug/ml; p = 0.0008) and was highest among stage III/IV patients. In a separate set of 193 pre-surgical samples, LRG1 was higher in patients with serous or clear cell ovarian cancer (145.82 65.99 ug/ml) compared to patients with benign gynecological diseases (82.53 76.67 ug/ml, p < 0.0001). CA125 and LRG1 levels were moderately correlated (r = 0.47, p < 0.0001). LRG1 mRNA levels were higher in ovarian cancer tissues and cell lines compared to their normal counterparts when analyzed by gene microarray and RT-PCR. LRG1 protein was detected in ovarian cancer tissue samples and cell lines by immunocytochemistry and Western blotting. Multiple iosforms of LRG1 were observed by Western blot and were shown to represent different glycosylation states by digestion with glycosidase. LRG1 protein was also detected in the conditioned media of ovarian cancer cell culture by ELISA, Western blotting, and mass spectrometry. Conclusions. Serum LRG1 was significantly elevated in women with ovarian cancer compared to healthy women and women with benign gynecological disease, and was only moderately correlated with CA125. Ovarian cancer cells secrete LRG1 and may contribute directly to the elevated levels of LRG1 observed in the serum of ovarian cancer patients. Future studies will determine whether LRG1 may serve as a biomarker for presurgical diagnosis, disease recurrence, and/or as a target for therapy.

AB - Background. New biomarkers that replace or are used in conjunction with the current ovarian cancer diagnostic antigen, CA125, are needed for detection of ovarian cancer in the presurgical setting, as well as for detection of disease recurrence. We previously demonstrated the upregulation of leucine-rich alpha-2-glycoprotein-1 (LRG1) in the sera of ovarian cancer patients compared to healthy women using quantitative mass spectrometry. Methods. LRG1 was quantified by ELISA in serum from two relatively large cohorts of women with ovarian cancer and benign gynecological disease. The expression of LRG1 in ovarian cancer tissues and cell lines was examined by gene microarray, reverse-transcriptase polymerase chain reaction (RT-PCR), Western blot, immunocytochemistry and mass spectrometry. Results. Mean serum LRG1 was higher in 58 ovarian cancer patients than in 56 healthy women (89.33 77.90 vs. 42.99 9.88 ug/ml; p = 0.0008) and was highest among stage III/IV patients. In a separate set of 193 pre-surgical samples, LRG1 was higher in patients with serous or clear cell ovarian cancer (145.82 65.99 ug/ml) compared to patients with benign gynecological diseases (82.53 76.67 ug/ml, p < 0.0001). CA125 and LRG1 levels were moderately correlated (r = 0.47, p < 0.0001). LRG1 mRNA levels were higher in ovarian cancer tissues and cell lines compared to their normal counterparts when analyzed by gene microarray and RT-PCR. LRG1 protein was detected in ovarian cancer tissue samples and cell lines by immunocytochemistry and Western blotting. Multiple iosforms of LRG1 were observed by Western blot and were shown to represent different glycosylation states by digestion with glycosidase. LRG1 protein was also detected in the conditioned media of ovarian cancer cell culture by ELISA, Western blotting, and mass spectrometry. Conclusions. Serum LRG1 was significantly elevated in women with ovarian cancer compared to healthy women and women with benign gynecological disease, and was only moderately correlated with CA125. Ovarian cancer cells secrete LRG1 and may contribute directly to the elevated levels of LRG1 observed in the serum of ovarian cancer patients. Future studies will determine whether LRG1 may serve as a biomarker for presurgical diagnosis, disease recurrence, and/or as a target for therapy.

UR - http://www.scopus.com/inward/record.url?scp=77957727526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957727526&partnerID=8YFLogxK

U2 - 10.1186/1757-2215-3-21

DO - 10.1186/1757-2215-3-21

M3 - Article

C2 - 20831812

AN - SCOPUS:77957727526

VL - 3

JO - Journal of Ovarian Research

JF - Journal of Ovarian Research

SN - 1757-2215

IS - 1

M1 - 21

ER -